SPN-810
810P204
Phase 3 small_molecule terminated
Quick answer
SPN-810 for Attention Deficit Hyperactivity Disorder (ADHD) is a Phase 3 program (small_molecule) at SUPERNUS PHARMACEUTICALS, INC. with 2 ClinicalTrials.gov record(s).
Program details
- Company
- SUPERNUS PHARMACEUTICALS, INC.
- Indication
- Attention Deficit Hyperactivity Disorder (ADHD)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated